Table 1 Baseline characteristics
From: Effects of antivirals on patients with COVID-19 breakthrough
SoC + antiviral (n = 74) | SoC (n = 68) | Overall (n = 142) | |
|---|---|---|---|
Male gender | 34 (45.9) | 24 (35.3) | 58 (40.8) |
Age (years) | 37.3 ± 9.6 | 35.0 ± 9.9 | 36.2 ± 9.8 |
< 65 | 71 (95.9) | 68 (100.0) | 97.9 |
≥ 65 | 3 (4.1) | 0 (0.0) | 3 (2.1) |
Weight (kg) | 62.3 ± 13.1 | 58.6 ± 11.8 | 60.5 ± 12.6 |
Height (cm) | 161.3 ± 7.7 | 160.0 ± 8.4 | 160.7 ± 8.0 |
Educational status | |||
Tertiary and above | 69 (93.2) | 59 (86.8) | 128 (90.1) |
Secondary and below | 5 (6.8) | 9 (13.2) | 14 (9.1) |
Comorbidities | |||
Endocrine diseases1 | 3 (4.1) | 3 (4.4) | 6 (4.2) |
Cardiovascular diseases2 | 8 (10.8) | 6 (8.8) | 14 (9.9) |
Respiratory diseases3 | 2 (2.7) | 5 (7.4) | 7 (4.9) |
Gastrointestinal diseases4 | 3 (4.1) | 0 (0.0) | 3 (2.1) |
Musculoskeletal disorders5 | 3 (4.1) | 0 (0.0) | 3 (2.1) |
Cancers | 0 (0.0) | 3 (4.4) | 3 (2.1) |
First vaccine jab | |||
AZD12226 | 70 (94.6) | 59 (86.8) | 129 (90.8) |
mRNA-12737 | 1 (1.4) | 1 (1.5) | 2 (1.4) |
BNT162b28 | 2 (2.7) | 2 (2.9) | 4 (2.8) |
BBIBP-CorV9 | 1 (1.4) | 6 (8.8) | 7 (4.9) |
Second vaccine jab | |||
AZD12226 | 69 (93.2) | 59 (86.8) | 128 (90.1) |
mRNA-12737 | 1 (1.4) | 1 (1.5) | 2 (1.4) |
BNT162b28 | 3 (4.1) | 5 (7.4) | 8 (5.6) |
BBIBP-CorV9 | 1 (1.4) | 3 (4.4) | 4 (2.8) |
Concurrent medications | |||
Corticosteroids10 | 16 (21.6) | 12 (17.6) | 28 (19.7) |
Anticoagulants11 | 2 (2.7) | 1 (1.5) | 3 (2.1) |
Antipyretic agents12 | 62 (83.8) | 42 (61.8) | 104 (73.2) |
Antibiotics13 | 19 (25.7) | 9 (13.2) | 28 (19.7) |
Herbal medications14 | 10 (13.5) | 15 (22.1) | 25 (17.6) |